Nathan Connell: The Changing Landscape of von Willebrand Disease Diagnosis and Management
Nathan Connell, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared a post on Linkedln about a recent article he and his colleagues co-authored, published in Haemophilia, adding:
“In 2024, I traveled to Föglö in the Åland archipelago for the Seventh Åland Island Meeting on von Willebrand Disease.
I wrote then about the significance of returning to the place where Erik von Willebrand first described the disorder nearly a century ago.
It was a rare opportunity to connect the history of the field with the current work needed to improve diagnosis, treatment, and access for people living with VWD.
I am pleased to share that our meeting summary has now been published in Haemophilia Journal: ‘Seventh Åland Island Meeting on von Willebrand Disease.’
The manuscript captures several themes that remain central to the future of VWD care:
- VWD is common, heterogeneous, and still under-recognized, with diagnostic delays that continue to affect quality of life and treatment access.
- Bleeding assessment tools, newer VWF activity assays such as VWF and VWF, genotype-informed interpretation, and standardized diagnostic pathways are changing the diagnostic landscape.
- Women’s health remains a central priority, including heavy menstrual bleeding, pregnancy, postpartum hemorrhage, iron deficiency, and the need for stronger hematology–gynecology collaboration.
- Defining ‘severe VWD’ more consistently is essential for clinical decision-making, prophylaxis access, reimbursement, and clinical trial design.
- Emerging data support prophylaxis for selected patients with clinically severe VWD, while personalized and pharmacokinetic-guided approaches require further study.
- The next phase of progress will depend on multidisciplinary collaboration among clinicians, laboratory scientists, geneticists, biologists, patient communities, and industry partners.
I was grateful to contribute the section on navigating the diagnostic landscape in VWD, including the persistent challenge of delayed diagnosis, the appropriate role of bleeding assessment tools, and the need to adapt guideline-based diagnostic algorithms to real-world and differently resourced settings.
Thank you to Octapharma for supporting this meeting and making it possible for us to gather in Åland for such a thoughtful and productive discussion.
Congratulations and thanks to my coauthors and colleagues, including Riitta Lassila, Erik Berntorp, Ruben Bierings, Fernando Corrales-Medina, Augusto Federici, Veronica Flood, Floor Heubel-Moenen, Jill Johnsen, Geoffrey Kuppens, Davide Matino, Carolyn Millar, Ingmar Schön, Anish Sharda, Robert Sidonio, Alok Srivastava, Timea Szanto, and Angela Weyand.”
Title: Seventh Åland Island Meeting on von Willebrand Disease
Auhtors: Riitta Lassila, Ruben Bierings, Nathan T. Connell, Fernando F. Corrales-Medina, Augusto B. Federici, Veronica H. Flood, Floor Heubel-Moenen, Jill M. Johnsen, Geoffrey Kuppens, Davide Matino, Carolyn Millar, Ingmar Schoen, Anish Sharda, Robert F. Sidonio Jr, Alok Srivastava, Timea Szanto, Angela C. Weyand, Erik Berntorp

Other posts featuring Nathan Connell on Hemostasis Today.
-
Nov 19, 2026, 16:27263 PolyU Students and Staff Unite to Donate Blood – Hong Kong Red Cross Blood Transfusion Service
-
Nov 19, 2026, 16:16Billy Otieno: The Future of Blood Donation Lies Beyond Collection
-
Nov 19, 2026, 15:58Hema Goyal: Hematocon 2026 Bringing Together Knowledge, Innovation and Excellence in Hematology
-
Nov 19, 2026, 15:44Chukwuemeka Amarachi: Understanding Complex Blood Grouping Beyond Routine ABO And RhD Typing
-
Nov 19, 2026, 14:19Long-Read Sequencing Is Closing Diagnostic Gaps in Inherited Bleeding Disorders
-
Nov 19, 2026, 13:36Raja Prince: Protein S Silencing and the Future of Hemostatic Therapy
-
Nov 19, 2026, 13:26M. Sekip Altunkan: The Thrombotic Risk of Andexanet Alfa
-
Nov 19, 2026, 13:18Felice Gragnano: Personalizing Antiplatelet Therapy After PCI
-
Nov 19, 2026, 13:11When Postpartum Warning Signs Are Ignored – National Blood Clot Alliance